Lonza widens cell and gene therapy suite by way of launching of two new products, which are – TheraPEAK AmpliCell Cytokines as well as TheraPEAK 293-GT Medium.
The additions happened to be aimed at elevating the scalability as well as consistency of advanced therapy production as per the Good Manufacturing Practice (GMP) conditions.
The TheraPEAK AmpliCell Cytokines happen to be designed in order to support immune cell expansion, activation, and, of course, differentiation. Manufactured through using a mammalian expression system, the cytokines get engineered for high biological activity as well as structural fidelity, hence providing advantages as compared to the bacterial systems when it comes to folding, glycosylation along with batch consistency. Lonza confirmed that the product is intended to enhance the predictability in research and also clinical manufacturing environments.
Meanwhile, TheraPEAK 293-GT Medium, which is chemically defined and also an animal-origin-free formulation, has gone on to be optimized for adeno-associated virus (AAV) production in suspension HEK293 cells. The company said that the medium happens to be compatible with the present transfection reagents as well as the AAV enhancers and at the same time also supports high full-to-empty capsid ratios, which happen to be an important metric when it comes to gene therapy vector production.
It is well to be noted that both the products happen to be a part of the TheraPEAK portfolio by Lonza, which, as per the company, has been used in FDA-approved therapies as well as across 130 clinical trials throughout the world.
Lonza’s Head of Bioscience, Specialized Modalities, Mike Goetter, said that the introduction of AmpliCell Cytokines as well as the 293-GT Medium to their TheraPEAK Range massively elevates their offering, and as Lonza widens cell and gene therapy suite, it gives them dependable solutions in order to support their drug development endeavors.
